Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19252084 | TOPICAL COMPOSITION | June 2025 | January 2026 | Allow | 7 | 1 | 0 | Yes | No |
| 19177248 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | April 2025 | August 2025 | Allow | 4 | 1 | 0 | No | No |
| 18814513 | Therapeutic mouthwash containing doxycycline and method of preventing COVID infection using the therapeutic mouthwash | August 2024 | June 2025 | Abandon | 9 | 0 | 1 | No | No |
| 18773435 | TOPICAL PEEL-OFF CREAM FOR NUMBING PAIN DURING SKIN-RELATED PROCEDURES | July 2024 | May 2025 | Abandon | 10 | 1 | 0 | No | No |
| 18764024 | FORMULATIONS AND METHODS FOR SKIN CARE OR HYALURONIC ACID SYNTHESIS | July 2024 | January 2025 | Allow | 7 | 1 | 0 | No | No |
| 18760811 | METHODS FOR TREATING MAJOR DEPRESSIVE DISORDER AND TREATMENT-RESISTANT DEPRESSION | July 2024 | January 2026 | Abandon | 19 | 3 | 0 | No | No |
| 18670632 | EFFECTIVE TREATMENT OF DEPRESSION IN PATIENTS HAVING IMPAIRED LEARNING AND/OR MEMORY OR CERTAIN EEG CHARACTERISTICS WITH A BENZYLPIPERAZINE-AMINOPYRIDINE AGENT | May 2024 | March 2025 | Abandon | 10 | 1 | 0 | No | No |
| 18668552 | 4,5-BIS(4-BROMOPHENYL)-2-(4-BROMOPHENYL)-1-HEXYL-1H-IMIDAZOLE AS AN ANTIMICROBIAL COMPOUND | May 2024 | July 2024 | Allow | 2 | 0 | 0 | No | No |
| 18662706 | 1-[4,5-BIS(4-CHLOROPHENYL)-1-HEXYL-1H-IMIDAZOL-2-YL]-2-NAPHTHOL AS AN ANTIMICROBIAL COMPOUND | May 2024 | July 2024 | Allow | 2 | 0 | 0 | No | No |
| 18631518 | 6-(4,5-BIS(4-BROMOPHENYL)-2-(4-METHOXYPHENYL)-1H-IMIDAZOL-1-YL)HEXANOIC ACID AS AN ANTIMICROBIAL COMPOUND | April 2024 | October 2024 | Allow | 6 | 1 | 0 | No | No |
| 18687803 | BIFLAVONE COMPOUND AGAINST I-TYPE HERPES SIMPLEX VIRUS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | February 2024 | August 2024 | Allow | 5 | 1 | 0 | No | No |
| 18436527 | PREPARATION AND USES OF OBETICHOLIC ACID | February 2024 | October 2025 | Abandon | 21 | 1 | 0 | No | No |
| 18435817 | PHARMACEUTICAL COMPOSITION COMPRISING A DIPHENYLPYRAZINE DERIVATIVE | February 2024 | July 2025 | Abandon | 17 | 2 | 1 | No | No |
| 18429339 | TOPICAL NALOXONE COMPOSITIONS AND METHODS FOR USING THE SAME | January 2024 | February 2025 | Abandon | 13 | 1 | 1 | No | No |
| 18418112 | METHOD OF SCREENING FOR AGENTS FOR DIFFERENTIATING STEM CELLS | January 2024 | November 2025 | Abandon | 22 | 0 | 1 | No | No |
| 18411139 | COMBINATION THERAPY FOR TREATING CANCER | January 2024 | June 2025 | Abandon | 17 | 0 | 1 | No | No |
| 18398241 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF EDARAVONE AND METHOD OF ADMINISTERING SAME | December 2023 | July 2025 | Allow | 19 | 1 | 0 | Yes | No |
| 18534517 | HETEROCYCLIC GLP-1 AGONISTS | December 2023 | July 2025 | Allow | 20 | 1 | 1 | No | No |
| 18528976 | METHODS FOR TREATING HEMOLYTIC DISEASES AND SICKLE CELL DISEASE | December 2023 | September 2025 | Abandon | 22 | 2 | 1 | No | No |
| 18529368 | LASOFOXIFENE COMBINATION TREATMENT OF ER+ BREAST CANCER THAT HAS PROGRESSED ON A CDK4/6 INHIBITOR | December 2023 | September 2024 | Abandon | 10 | 1 | 1 | Yes | No |
| 18520024 | DOSING REGIMEN FOR INJECTABLE CETIRIZINE | November 2023 | March 2026 | Abandon | 27 | 3 | 0 | Yes | No |
| 18517062 | Method Of Treating Major Depressive Disorder | November 2023 | February 2025 | Allow | 15 | 2 | 0 | No | No |
| 18511426 | 3,3'-(hydrazine-1,2-diyl)bis(1-(naphthalen-2-yloxy)propan-2-ol) AS AN ECOFRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.) | November 2023 | March 2024 | Allow | 4 | 1 | 0 | No | No |
| 18511800 | 3,3'-(hydrazine-1,2-diyl)bis(1-(naphthalen-2-yloxy)propan-2-ol) AS AN ECOFRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.) | November 2023 | May 2024 | Allow | 6 | 2 | 0 | No | No |
| 18508826 | Method Of Treating Major Depressive Disorder | November 2023 | November 2025 | Allow | 24 | 4 | 0 | No | No |
| 18560543 | THERAPEUTIC AMINOINDANE COMPOUNDS AND COMPOSITIONS | November 2023 | September 2025 | Abandon | 22 | 3 | 1 | Yes | No |
| 18387918 | 4,5-BIS(4-BROMOPHENYL)-2-(4-BROMOPHENYL)-1-HEXYL-1H-IMIDAZOLE AS AN ANTIMICROBIAL COMPOUND | November 2023 | April 2024 | Allow | 6 | 1 | 1 | No | No |
| 18503823 | 1-[4,5-BIS(4-CHLOROPHENYL)-1-HEXYL-1H-IMIDAZOL-2-YL]-2-NAPHTHOL AS AN ANTIMICROBIAL COMPOUND | November 2023 | April 2024 | Allow | 5 | 1 | 1 | No | No |
| 18491644 | COMPOSITIONS AND METHODS FOR TREATING PAIN WITH WOGONIN | October 2023 | September 2024 | Allow | 11 | 1 | 0 | No | No |
| 18489846 | USE OF PRIDOPIDINE FOR TREATING DYSTONIAS | October 2023 | October 2025 | Allow | 24 | 2 | 1 | Yes | No |
| 18488092 | NLRP3 MODULATORS | October 2023 | February 2025 | Allow | 16 | 1 | 1 | No | No |
| 18463851 | Methods of Treating Ovarian Cancer | September 2023 | September 2025 | Allow | 24 | 1 | 1 | Yes | No |
| 18238694 | 3,3'-(hydrazine-1,2-diyl)bis(1-(naphthalen-2-yloxy)propan-2-ol) AS AN ECOFRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.) | August 2023 | December 2023 | Allow | 3 | 1 | 1 | No | No |
| 18455813 | USE OF (1S,3S)-3-AMINO-4-(DIFLUOROMETHYLIDENE) CYCLOPENTANE-1-CARBOXYLIC ACID AND (S)-3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID IN THE TREATMENT OF TINNITUS, ACUTE SENSORINEURAL HEARING LOSS, MENIERE’S DISEASE, TOURETTE’S SYNDROME, ATTENTION DEFICIT HYPERACTIVITY DISORDER AND ADDICTION | August 2023 | May 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18228476 | STABLE WOUND CARE FORMULATION | July 2023 | July 2025 | Abandon | 24 | 1 | 1 | No | No |
| 18361526 | PYRAZOLEAMIDE DERIVATIVES | July 2023 | February 2026 | Allow | 31 | 1 | 0 | No | No |
| 18261923 | PHARMACEUTICAL COMPOSITION COMPRISING A DIPHENYLPYRAZINE DERIVATIVE | July 2023 | November 2025 | Abandon | 28 | 0 | 1 | No | No |
| 18221183 | POLYMERIC CLOTRIMAZOLE BIOFILM FOR THE TREATMENT OF OTOMYCOSIS | July 2023 | November 2023 | Allow | 4 | 1 | 0 | No | No |
| 18217817 | PURINONE DERIVATIVE | July 2023 | February 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18215058 | TOPICAL FORMULATIONS OF NITROGLYCERIN | June 2023 | April 2024 | Allow | 9 | 1 | 1 | Yes | No |
| 18210625 | METHOD OF TREATING LAMINOPATHIES | June 2023 | February 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18205293 | CROMOLYN DERIVATIVES AND RELATED METHODS OF IMAGING AND TREATMENT | June 2023 | January 2026 | Allow | 31 | 2 | 0 | Yes | No |
| 18326636 | FIXED DOSE COMBINATIONS AND FORMULATIONS COMPRISING ETC1002 AND ONE OR MORE STATINS AND METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE | May 2023 | January 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18324754 | METHODS OF TREATING INFECTIONS IN OVERWEIGHT AND OBESE PATIENTS USING ANTIBIOTICS | May 2023 | October 2025 | Allow | 29 | 2 | 0 | No | No |
| 18311415 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION OF EDARAVONE AND METHOD OF ADMINISTERING SAME | May 2023 | March 2024 | Allow | 10 | 1 | 0 | No | No |
| 18309069 | MORPHINE FORMULATIONS | April 2023 | January 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18140914 | METHODS OF MANAGING CONDITIONED FEAR WITH NEUROKININ RECEPTOR ANTAGONISTS | April 2023 | August 2025 | Abandon | 28 | 2 | 1 | No | No |
| 18299504 | CANNABINOID DERIVATIVES AND THEIR USE | April 2023 | November 2024 | Allow | 19 | 3 | 0 | Yes | No |
| 18299009 | METHODS OF MODULATING TETRABENAZINE METABOLITES PLASMA LEVELS USING BUPROPION | April 2023 | March 2025 | Abandon | 23 | 3 | 0 | No | Yes |
| 18298811 | INOSITOL PHOSPHATE COMPOUNDS FOR USE IN INCREASING TISSULAR PERFUSION | April 2023 | April 2025 | Abandon | 25 | 2 | 1 | No | Yes |
| 18296628 | METHODS OF TREATMENT USING BEMPEDOIC ACID | April 2023 | July 2024 | Abandon | 15 | 2 | 0 | Yes | No |
| 18194634 | Effect of YEL002 on Psychological and Psychiatric Factors in Health and Disease | April 2023 | May 2025 | Abandon | 25 | 2 | 0 | No | No |
| 18192234 | METHODS OF TREATING SOCIAL FUNCTION DISORDERS | March 2023 | July 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18188341 | PREPARATION AND USES OF OBETICHOLIC ACID | March 2023 | February 2024 | Abandon | 11 | 1 | 1 | No | No |
| 18187380 | SUBSTITUTED CHROMANES, ANALOGS THEREOF, AND METHODS OF USE AND SYNTHESIS | March 2023 | May 2025 | Allow | 25 | 2 | 0 | No | No |
| 18245518 | TREATMENT FOR SCHIZOPHRENIA | March 2023 | March 2026 | Abandon | 36 | 1 | 0 | No | No |
| 18117808 | STABLE PHARMACEUTICAL COMPOSITIONS OF APIXABAN | March 2023 | September 2024 | Allow | 19 | 3 | 1 | Yes | No |
| 18024625 | Method of Treating Cancer Using FABP5 Inhibitors | March 2023 | March 2026 | Abandon | 36 | 1 | 0 | No | No |
| 18023399 | Low Dose Topical Composition Comprising Triamcinolone Acetonide or Salt Thereof | February 2023 | February 2026 | Abandon | 35 | 1 | 0 | No | No |
| 18022522 | TOPICAL ROFLUMILAST COMPOSITIONS AND USES THEREOF | February 2023 | February 2026 | Abandon | 36 | 1 | 0 | No | No |
| 18111007 | THERAPEUTIC OR PREVENTIVE AGENT FOR EYE DISEASES | February 2023 | June 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18042108 | CRYSTAL OF COMPOUND X7 HYDROCHLORIDE AND ITS PREPARATION METHOD AND APPLICATION | February 2023 | January 2026 | Allow | 35 | 1 | 0 | No | No |
| 18167915 | COMPOSITION AND METHOD FOR TREATMENT OF DEPRESSION AND PSYCHOSIS IN HUMANS | February 2023 | March 2025 | Abandon | 25 | 1 | 1 | No | No |
| 18167809 | PHARMACEUTICAL FORMULATIONS CONTAINING CORTICOSTEROIDS FOR TOPICAL ADMINISTRATION | February 2023 | September 2025 | Abandon | 31 | 0 | 1 | No | No |
| 18019981 | THERAPIES FOR TREATING AML AND USES OF RARA AGONISTS, HYPOMETHYLATING AGENTS, AND BCL-2 INHIBITORS | February 2023 | February 2026 | Abandon | 36 | 1 | 0 | No | No |
| 18106378 | HETEROCYCLIC GLP-1 AGONISTS | February 2023 | September 2023 | Allow | 7 | 1 | 0 | Yes | No |
| 18165085 | POLYMERIC CLOTRIMAZOLE BIOFILM FOR THE TREATMENT OF OTOMYCOSIS | February 2023 | October 2023 | Allow | 8 | 1 | 1 | No | No |
| 18160878 | ORAL COMPOSITION OF CELECOXIB FOR TREATMENT OF PAIN | January 2023 | May 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18096598 | KINASE INHIBITOR SALTS AND COMPOSITIONS THEREOF | January 2023 | April 2024 | Allow | 15 | 3 | 0 | No | No |
| 18152034 | TOPICAL FORMULATIONS OF CYCLOOXYGENASE INHIBITORS AND THEIR USE | January 2023 | August 2023 | Allow | 8 | 1 | 0 | No | No |
| 18094870 | METHOD TO DELIVER ANTIFIBRINOLYTIC DRUGS TO MITIGATE DAMAGE TO THE BRAIN CAUSED BY CONCUSSIVE IMPACT | January 2023 | November 2025 | Allow | 34 | 1 | 0 | Yes | No |
| 18014438 | THROMBOXANE RECEPTOR ANTAGONIST FORMULATIONS | January 2023 | March 2026 | Allow | 38 | 3 | 0 | Yes | No |
| 18091053 | LIQUID PHARMACEUTICAL FORMULATIONS OF QUINOLINES | December 2022 | August 2025 | Abandon | 32 | 4 | 1 | No | No |
| 18146127 | OXYMETAZOLINE COMPOSITIONS | December 2022 | December 2025 | Allow | 36 | 3 | 0 | Yes | No |
| 18087646 | NANOEMULSION FORMULATION FOR TREATING DISBETES MELLITUS (DM) | December 2022 | August 2025 | Abandon | 32 | 6 | 0 | Yes | No |
| 18011495 | COMPOSITION FOR TOPICAL DERMATOLOGICAL DELIVERY | December 2022 | October 2025 | Abandon | 33 | 4 | 1 | Yes | Yes |
| 18063574 | METHODS AND COMPOSITIONS FOR ORAL PILOCARPINE LIQUID | December 2022 | July 2025 | Allow | 31 | 5 | 1 | Yes | No |
| 18000497 | METHODS FOR TREATING MAJOR DEPRESSIVE DISORDER AND TREATMENT-RESISTANT DEPRESSION | December 2022 | May 2025 | Abandon | 29 | 1 | 0 | No | No |
| 17993799 | PHARMACEUTICAL FORMULATIONS CONTAINING CORTICOSTEROIDS FOR TOPICAL ADMINISTRATION | November 2022 | April 2024 | Allow | 17 | 2 | 1 | No | No |
| 17993806 | PHARMACEUTICAL FORMULATIONS CONTAINING CORTICOSTEROIDS FOR TOPICAL ADMINISTRATION | November 2022 | August 2023 | Allow | 8 | 1 | 0 | No | No |
| 17926388 | COMPOSITION AND METHODS OF RETINOIC ACID | November 2022 | January 2026 | Abandon | 38 | 1 | 0 | No | No |
| 17973133 | IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | October 2022 | August 2024 | Allow | 22 | 2 | 0 | No | No |
| 18047208 | POLYPHOSPHAZENES, METHODS OF MAKING, AND USES THEREOF | October 2022 | September 2025 | Abandon | 35 | 1 | 1 | No | No |
| 18046350 | TRANSPORE DELIVERY OF STEROIDS AND LARGE MOLECULES | October 2022 | September 2023 | Abandon | 11 | 0 | 0 | No | No |
| 18045047 | COMPOSITION FOR PREVENTION, AMELIORATION, OR TREATMENT OF URINATION-RELATED DISEASES COMPRISING CEPHALOTOCIN | October 2022 | December 2025 | Allow | 38 | 1 | 0 | Yes | No |
| 17907291 | AN NK-1 RECEPTOR ANTAGONIST FOR TREATING A DISEASE SELECTING FROM SEPSIS, SEPTIC SHOCK, ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) OR MULTIPLE ORGAN DYSFUNCTION SYNDROME (MODS) | September 2022 | December 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17907305 | NEW THERAPEUTIC TARGETS WITH AN ANTI-INFLAMMATORY AND ANTI-INTERFERON EFFECT | September 2022 | December 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17907220 | DETECTION AND TREATMENT OF INTESTINAL FIBROSIS | September 2022 | December 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17914146 | QUINOLINE COMPOUNDS FOR TREATING RESPIRATORY DISORDERS AND VIRAL INFECTIONS | September 2022 | January 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17933703 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | September 2022 | March 2023 | Allow | 6 | 2 | 0 | Yes | No |
| 17906348 | PREPARATION OF CYCLOSPORIN DERIVATIVES | September 2022 | November 2025 | Allow | 38 | 1 | 0 | No | No |
| 17932260 | METHODS OF TREATING LYMPHEDEMA WITH DEUPIRFENIDONE | September 2022 | November 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17931468 | METHODS FOR SOLID TUMOR TREATMENT | September 2022 | June 2025 | Allow | 33 | 1 | 0 | No | No |
| 17906186 | DIETARY SUPPLEMENT COMPRISING ALDEHYDE FUNCTIONAL MONOTERPENOIDS | September 2022 | February 2026 | Allow | 41 | 2 | 1 | No | No |
| 17900080 | PARENTERAL FORMULATIONS OF TREPROSTINIL | August 2022 | February 2024 | Abandon | 18 | 1 | 0 | No | No |
| 17898082 | COMPOSITIONS AND METHODS FOR TREATING MOTOR DISORDERS | August 2022 | July 2025 | Abandon | 35 | 4 | 0 | No | No |
| 17889931 | (S)-N-HYDROXY-2-(2-(4-METHOXYPHENYL)BUTANAMIDO)THIAZOLE-5-CARBOXAMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | August 2022 | April 2025 | Abandon | 32 | 0 | 1 | No | No |
| 17889541 | METHOD OF TREATING OR PREVENTING NEURODEGENERATION | August 2022 | April 2024 | Abandon | 20 | 1 | 0 | No | No |
| 17883687 | STABLE TOPICAL COMPOSITIONS OF FENOLDOPAM | August 2022 | August 2024 | Abandon | 24 | 2 | 0 | No | No |
| 17883502 | EFFECTS OF MESCALINE AND OF MESCALINE ANALOGS (SCALINES) TO ASSIST PSYCHOTHERAPY | August 2022 | March 2025 | Abandon | 32 | 5 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BARSKY, JARED.
With a 27.8% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 11.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BARSKY, JARED works in Art Unit 1628 and has examined 852 patent applications in our dataset. With an allowance rate of 51.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 27 months.
Examiner BARSKY, JARED's allowance rate of 51.8% places them in the 14% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by BARSKY, JARED receive 2.56 office actions before reaching final disposition. This places the examiner in the 75% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by BARSKY, JARED is 27 months. This places the examiner in the 71% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +21.0% benefit to allowance rate for applications examined by BARSKY, JARED. This interview benefit is in the 65% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 16.3% of applications are subsequently allowed. This success rate is in the 13% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 28.8% of cases where such amendments are filed. This entry rate is in the 41% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 41.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 39% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 64.0% of appeals filed. This is in the 44% percentile among all examiners. Of these withdrawals, 71.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 47.3% are granted (fully or in part). This grant rate is in the 42% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 0.5% of allowed cases (in the 60% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.8% of allowed cases (in the 67% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.